Journal article · 2022

Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases

Mark D. Andrews, Kevin Neil Dack, Marcel John de Groot, Maja Lambert, Carl Johan Sennbro, Mogens Larsen, Martin Stahlhut

Journal of Medicinal Chemistry, 65(13), 8828–8842 · Published 29 June 2022 · DOI 10.1021/acs.jmedchem.2c00422

View at the publisherCite this paper

In brief

“Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases” is a 2022 journal article by Mark D. Andrews and 6 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 38 citations as of 21 November 2026, which puts it in the top 7% of works published in 2022 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
38
Most cited in
2025 (12)
Field-weighted impact
2.44
References
45
Authors
7

Abstract

Interleukin 17A (IL-17A) is an interleukin cytokine whose dysregulation is implicated in autoimmune disorders such as psoriasis, and monoclonal antibodies against the IL-17A pathway are now well-established and very effective treatments. This article outlines the work that led to the identification of 23 as an oral, small-molecule protein–protein interaction modulator (PPIm) clinical development candidate. Protein… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022). Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases. Journal of Medicinal Chemistry, 65(13), 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422

MLA 9

Andrews, Mark D., et al. “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases.” Journal of Medicinal Chemistry, vol. 65, no. 13, 2022, pp. 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422.

Chicago

Andrews, Mark D., Kevin Neil Dack, Marcel John de Groot, Maja Lambert, Carl Johan Sennbro, Mogens Larsen, and Martin Stahlhut. 2022. “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases.” Journal of Medicinal Chemistry 65 (13): 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422.

Harvard

Andrews, M. D. et al. (2022) ‘Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases’, Journal of Medicinal Chemistry, 65(13), pp. 8828–8842. doi:10.1021/acs.jmedchem.2c00422.

IEEE

M. D. Andrews et al., “Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases,” Journal of Medicinal Chemistry, vol. 65, no. 13, pp. 8828–8842, 2022, doi: 10.1021/acs.jmedchem.2c00422.

BibTeX

@article{andrews2022discovery,
  title     = {{Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases}},
  author    = {Andrews, Mark D. and Dack, Kevin Neil and de Groot, Marcel John and Lambert, Maja and Sennbro, Carl Johan and Larsen, Mogens and Stahlhut, Martin},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2022},
  volume    = {65},
  number    = {13},
  pages     = {8828--8842},
  doi       = {10.1021/acs.jmedchem.2c00422},
  url       = {https://doi.org/10.1021/acs.jmedchem.2c00422}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
202344
20241111
20251212
202699

Its field-weighted citation impact is 2.44: it has been cited 2.44 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis

  • IL-17A
  • psoriasis
  • oral bioavailability
  • Rule of 5
  • small molecule drug discovery
  • structure-activity optimization
  • inflammatory diseases
  • monoclonal antibody alternatives

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Andrews, M. D., Dack, K. N., de Groot, M. J., Lambert, M., Sennbro, C. J., Larsen, M., & Stahlhut, M. (2022). Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases. Journal of Medicinal Chemistry, 65(13), 8828–8842. https://doi.org/10.1021/acs.jmedchem.2c00422

How many times has this paper been cited?

38 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Mark D. Andrews, Kevin Neil Dack, Marcel John de Groot, Maja Lambert, Carl Johan Sennbro, Mogens Larsen, Martin Stahlhut.

What is the DOI of this paper?

10.1021/acs.jmedchem.2c00422, permanently at https://doi.org/10.1021/acs.jmedchem.2c00422. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.